全文获取类型
收费全文 | 20661篇 |
免费 | 1118篇 |
国内免费 | 93篇 |
专业分类
耳鼻咽喉 | 242篇 |
儿科学 | 465篇 |
妇产科学 | 390篇 |
基础医学 | 2636篇 |
口腔科学 | 1120篇 |
临床医学 | 1478篇 |
内科学 | 5101篇 |
皮肤病学 | 388篇 |
神经病学 | 1822篇 |
特种医学 | 386篇 |
外科学 | 3245篇 |
综合类 | 205篇 |
一般理论 | 7篇 |
预防医学 | 1621篇 |
眼科学 | 463篇 |
药学 | 1194篇 |
中国医学 | 102篇 |
肿瘤学 | 1007篇 |
出版年
2024年 | 16篇 |
2023年 | 136篇 |
2022年 | 284篇 |
2021年 | 703篇 |
2020年 | 371篇 |
2019年 | 574篇 |
2018年 | 709篇 |
2017年 | 450篇 |
2016年 | 460篇 |
2015年 | 600篇 |
2014年 | 872篇 |
2013年 | 1035篇 |
2012年 | 1730篇 |
2011年 | 1734篇 |
2010年 | 959篇 |
2009年 | 867篇 |
2008年 | 1457篇 |
2007年 | 1506篇 |
2006年 | 1332篇 |
2005年 | 1278篇 |
2004年 | 1100篇 |
2003年 | 924篇 |
2002年 | 915篇 |
2001年 | 151篇 |
2000年 | 104篇 |
1999年 | 139篇 |
1998年 | 188篇 |
1997年 | 134篇 |
1996年 | 89篇 |
1995年 | 83篇 |
1994年 | 86篇 |
1993年 | 64篇 |
1992年 | 82篇 |
1991年 | 58篇 |
1990年 | 53篇 |
1989年 | 50篇 |
1988年 | 45篇 |
1987年 | 39篇 |
1986年 | 39篇 |
1985年 | 35篇 |
1984年 | 43篇 |
1983年 | 37篇 |
1982年 | 44篇 |
1981年 | 36篇 |
1980年 | 21篇 |
1979年 | 19篇 |
1978年 | 28篇 |
1977年 | 27篇 |
1976年 | 17篇 |
1973年 | 19篇 |
排序方式: 共有10000条查询结果,搜索用时 234 毫秒
111.
Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus 总被引:7,自引:0,他引:7
Berry JD Jones S Drebot MA Andonov A Sabara M Yuan XY Weingartl H Fernando L Marszal P Gren J Nicolas B Andonova M Ranada F Gubbins MJ Ball TB Kitching P Li Y Kabani A Plummer F 《Journal of virological methods》2004,120(1):87-96
There is a global need to elucidate protective antigens expressed by the SARS-coronavirus (SARS-CoV). Monoclonal antibody reagents that recognise specific antigens on SARS-CoV are needed urgently. In this report, the development and immunochemical characterisation of a panel of murine monoclonal antibodies (mAbs) against the SARS-CoV is presented, based upon their specificity, binding requirements, and biological activity. Initial screening by ELISA, using highly purified virus as the coating antigen, resulted in the selection of 103 mAbs to the SARS virus. Subsequent screening steps reduced this panel to seventeen IgG mAbs. A single mAb, F26G15, is specific for the nucleoprotein as seen in Western immunoblot while five other mAbs react with the Spike protein. Two of these Spike-specific mAbs demonstrate the ability to neutralise SARS-CoV in vitro while another four Western immunoblot-negative mAbs also neutralise the virus. The utility of these mAbs for diagnostic development is demonstrated. Antibody from convalescent SARS patients, but not normal human serum, is also shown to specifically compete off binding of mAbs to whole SARS-CoV. These studies highlight the importance of using standardised assays and reagents. These mAbs will be useful for the development of diagnostic tests, studies of SARS-CoV pathogenesis and vaccine development. 相似文献
112.
Testing genotypic and phenotypic resistance in human immunodeficiency virus type 1 isolates of clade B and other clades from children failing antiretroviral therapy 总被引:5,自引:0,他引:5
下载免费PDF全文
![点击此处可从《Journal of clinical microbiology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
113.
María Francisca Garijo José Fernando Val‐Bernal Alfonso Vega Daniel Val 《Pathology international》2008,58(12):787-791
Despite the frequent use of fine‐needle aspiration, core biopsy and surgery, postoperative spindle cell nodule (PSCN) is a rare pathological complication that may be diagnostically treacherous. Presented herein is the case of a 52‐year‐old woman who developed a 7 mm mammary nodular lesion 66 days after removal of an area of columnar cell hyperplasia involving cellular and architectural atypia, performed with the Mammotome Breast Biopsy System. The lesion was highly cellular and composed of intersecting fascicles of plump spindle cells with blunt‐ended elongated nuclei and nucleoli easily visible. Interspersed mononuclear cells and hemosiderin‐laden macrophages were evident. PSCN is a reactive, benign myofibroblastic proliferation. Differential diagnosis includes benign and malignant spindle cell lesions of the breast. Recognition of this reactive lesion will avoid overdiagnosis of spindle cell malignant tumor. Attention to clinicopathological and histological features should result in accurate recognition of this lesion. 相似文献
114.
Idiopathic CD4+ lymphocytopenia may be due to decreased bone marrow clonogenic capability 总被引:1,自引:0,他引:1
Isgrò A Sirianni MC Gramiccioni C Mezzaroma I Fantauzzi A Aiuti F 《International archives of allergy and immunology》2005,136(4):379-384
BACKGROUND: Idiopathic CD4+ lymphocytopenia is defined by a stable decrease of CD4+ T cells in the absence of any known cause of immune deficiency. The mechanisms responsible for the immunological impairment are still unknown, but a regenerative failure of hematopoietic stem/progenitor cells has been hypothesized. METHODS: We evaluated in the bone marrow (BM) of 5 patients with idiopathic CD4+ lymphocytopenia the phenotype of BM progenitor cells, their differentiation capacity with colony-forming cells and long-term culture-initiating cell assays, in parallel with the spontaneous IL-7 production in the patient sera. RESULTS: Compared with controls, a regenerative failure of hematopoietic stem cells has been observed, both in 'committed' and in 'uncommitted' progenitor cells, despite high IL-7 serum levels. The percentage of phenotypically primitive CD34+CD38-DR+ cells (this includes the lymphoid precursor cells) was decreased, suggesting an involvement of the more primitive BM compartment in the de novo T cell generation. CONCLUSIONS: Despite the low number of patients, due to the low incidence of the disease, the decrease of primitive precursors sustains the possibility that diminished stem cell precursors might contribute to the development of CD4+ T cell depletion. 相似文献
115.
116.
117.
Holt PG Sly PD Martinez FD Weiss ST Björkstén B von Mutius E Wahn U 《Nature immunology》2004,5(7):695-698
The spiraling costs of asthma treatment seem set to continue rising, given the equivocal performance of the latest generation of specific anti-inflammatory drugs in trials in adult asthmatics. We argue that the continuation of this trend is inevitable unless there is a substantial realignment of entrenched drug development policy in the pharmaceutical industry and a parallel shift in licensing policy by regulatory authorities to encourage the development of drugs capable of halting the progression from acute to chronic asthma when the disease first manifests in childhood. The theoretical framework for such an approach, including proof-of-principle data from studies in children with early-stage disease and a range of candidate drugs, already exists. What is needed is informed debate on the risks versus potential benefits of this approach. 相似文献
118.
Ludwig DL Witte L Hicklin DJ Prewett M Bassi R Burtrum D Pereira DS Jimenez X Fox F Saxena B Zhou Q Ma Y Kang X Patel D Barry M Kussie P Zhu Z Russell DA Petersen WL Jury TP Gaitan-Gaitan F Moran DL Delannay X Storrs BS Tou J Zupec ME Gustafson KS McIntyre J Tarnowski SJ Bohlen P 《Human antibodies》2004,13(3):81-90
Recombinant protein production in plants such as corn is a promising means to generate high product yields at low comparable production cost. The anti-EGFR monoclonal antibody C225, cetuximab, is a well-characterized receptor antagonist antibody recently approved for the treatment of refractory colorectal cancer. We initiated a study to test and compare the functional activity of glycosylated and aglycosylated C225 produced in stable transgenic corn seed. Both corn antibodies were shown to be functionally indistinguishable from mammalian-derived C225 in demonstrating high-affinity binding to the EGF receptor, blocking of ligand-dependent signaling, and inhibiting cell proliferation. In addition, consistent with cetuximab, both corn antibodies possessed strong anti-tumor activity in vivo. Acute dose primate pharmacokinetic studies, however, revealed a marked increase in clearance for the glycosylated corn antibody, while the aglycosylated antibody possessed in vivo kinetics similar to cetuximab. This experimentation established that corn-derived receptor blocking monoclonal antibodies possess comparable efficacy to mammalian cell culture-derived antibody, and offer a cost effective alternative to large-scale mammalian cell culture production. 相似文献
119.
Charles Frèche Francisque Leynadier Friedrich Horak David Hide Fernando Duce Gracia Manfred Goos Claus Bachert Attila Horvath Eva Antosova Muriel Verrecchia Paul Ben Soussen 《Annals of allergy, asthma & immunology》2002,89(3):304-310
BACKGROUND: Mizolastine is a nonsedating H1 histamine receptor antagonist with additional antiallergic properties currently marketed in Europe for the treatment of seasonal and perennial allergic rhinitis (PAR) and urticaria. OBJECTIVE: This multicenter, randomized, double-blind, parallel-group study was conducted to evaluate the efficacy and safety of mizolastine in PAR compared with loratadine and placebo. METHODS: After a 1-week placebo run-in period, 428 adult PAR patients received placebo (146 of 428), mizolastine 10 mg (141 of 428), or loratadine 10 mg (141 of 428) once daily for 28 days. Symptoms were evaluated by patients and physicians using a total nasal score, evaluating itching, rhinorrhea, nasal blockade, and sneezing severity. RESULTS: Mizolastine treatment resulted in a significantly greater decrease in patient-rated total nasal score than placebo after 2 weeks (D14; -42%, P < 0.001) and at the end of the treatment period (-46%, P = 0.01), and significantly greater than that observed with loratadine at D14 (P = 0.031). No significant difference in change in total nasal score was observed between loratadine and placebo at 2- and 4-week visits. The global safety was satisfactory and the incidence of adverse events was similar in the three treatment groups. CONCLUSIONS: Mizolastine provides effective symptom relief in PAR together with a satisfactory safety profile. Improvement with mizolastine was significantly greater than placebo throughout the study despite a large placebo effect. Also mizolastine's effects were greater those observed with loratadine after 2 weeks of treatment. 相似文献
120.
Deemer E Bertocci G Pierce MC Aguel F Janosky J Vogeley E 《Medical engineering & physics》2005,27(1):31-39
INTRODUCTION: Falls are a major cause of morbidity and mortality in children, but are also reported falsely in child abuse. Therefore, it is of interest to understand those factors which may lead to a higher likelihood of injury in a feet-first freefall. METHODS: We used laboratory freefall experiments and a 3-year-old Hybrid III anthropomorphic test dummy (ATD) to assess head and femur injury risk. Wet and dry linoleum impact surfaces were used from three fall heights: 22, 35 and 47 in. RESULTS: For a given fall height, dry surfaces were associated with higher head injury criteria (HIC) values than wet surfaces. Changes in fall height 22-47 in. did not significantly affect HIC values for falls onto either surface. Generally, compressive and bending femur loading increased significantly for wet as compared to dry linoleum. CONCLUSIONS: In simulated feet first freefall experiments up to 47 in. using a 3-year-old test dummy, a low risk of contact type head injury and femur fracture was found. However, both fall height and surface conditions influenced femur loading and head injury measures. Future efforts should explore the risk of head injury associated with angular acceleration in freefalls. 相似文献